As the largest single vaccination effort the global community has ever undertaken, ASHP believes the following are vital to an effective vaccination rollout:

• Enforce a transparent and rigorous process for vaccine development, approval, and postmarketing surveillance.
• Collaborate and coordinate with U.S. and international public health partners to establish and implement a framework for the ethical and equitable global distribution of vaccines.
• Engage, prepare, and protect the workforce of immunization personnel.
• Expand patient access to COVID-19 vaccines by leveraging a highly qualified and empowered clinical pharmacy workforce in all settings of care.
• Adhere to established best practices for proper storage and handling of vaccines throughout the supply chain from distribution to patient administration.
• Ensure equitable allocation of COVID-19 vaccines across populations and communities, prioritized for greatest public health impact.
• Achieve high acceptance and uptake of COVID-19 vaccines by minimizing vaccine hesitancy and misinformation.
• Seek innovative solutions for adverse drug event monitoring and documentation to improve the thoroughness, accuracy, and usefulness of data collection for improved vaccine safety.
• Ensure patient access to COVID-19 vaccines by preventing and removing financial barriers.
• Remain vigilant with continued research and comprehensive surveillance procedures for COVID-19 vaccine use, safety, and effectiveness.

EpiVax licenses COVID-19 vaccine to EVT
EpiVax has licensed its COVID-19 vaccine candidate, EPV-CoV-19, to EpiVax Therapeutics (EVT), formerly known as EpiVax Oncology.

Data-sharing platform could help planning for future pandemics
In response to the global pandemic, the authors of a new paper are calling for a robust centralized platform to improve international data sharing among...

Moderna discusses supplying 80M doses of mRNA-1273 to EU
Moderna is in discussions with the European Commission to supply 80 million doses of messenger RNA (mRNA)-1273, Moderna's COVID-19 vaccine candidate,...

Novavax begins phase II trial of COVID-19 vaccine
Novavax has dosed the first participants in a phase II portion of an ongoing clinical trial to investigate the immunogenicity and safety of NVX-CoV2373,...

Catalent to support AstraZeneca COVID-19 vaccine manufacturing
Catalent and AstraZeneca have signed an agreement to expand manufacturing support for an adenovirus vector-based COVID-19 vaccine from the University...